{
    "id": 3246,
    "name": "embryonal rhabdomyosarcoma",
    "source": "DOID",
    "definition": "A rhabdomyosarcoma wherein the mesenchymally-derived malignant cells resemble the primitive developing skeletal muscle of the embryo; it occurs most often in the head and neck area or in the genital or urinary organs. [url:http\\://en.wikipedia.org/wiki/Embryonal_rhabdomyosarcoma, url:http\\://www.cancer.gov/cancertopics/pdq/treatment/childrhabdomyosarcoma/Patient/page1]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3246",
    "evidence": [
        {
            "id": 20035,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYOD1 mutations aid the diagnosis of embryonal rhabdomyosarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 34797,
                "profileName": "MYOD1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3246,
                "name": "embryonal rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02567435",
            "title": "Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1435,
                    "therapyName": "Cyclophosphamide + Dactinomycin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02639546",
            "title": "Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03041701",
            "title": "Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5287,
                    "therapyName": "Dasatinib + Ganitumab",
                    "synonyms": null
                }
            ]
        }
    ]
}